Company / SG&A Expense
Matinas BioPharma Holdings, Inc. SG&A Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$8.7M
FY2024
5-year range
$8.7M / $11.1M
FY2020-FY2024
Trend
-21.4%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $10M to $9M over the past 2 years.
Based on SEC 10-K filings.
$9M in FY2024 with a 5-year CAGR of +1.8%.
Improved from $10M to $9M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -5.0%
- 5-Year CAGR
- +1.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +1.8%, indicating consistent growth.
- In FY2024, sg&a expense decreased 21.4% year-over-year.
- Peak sg&a expense was recorded in FY2023.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $8.7M | -21.4% |
| FY2023 | $11.1M | +9.0% |
| FY2022 | $10.2M | +0.0% |
| FY2021 | $10.2M | +1.8% |
| FY2020 | $10.0M | +25.4% |
| FY2019 | $8.0M | +4.4% |
| FY2018 | $7.6M | +58.7% |
| FY2017 | $4.8M | +11.7% |
| FY2016 | $4.3M | -10.5% |
| FY2015 | $4.8M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026